Partnership includes support for plasma-derived and rare disease therapies
GC Biopharma announced on May 14 that it signed a memorandum of understanding (MOU) with Merck Life Science Korea to cooperate on biopharmaceutical manufacturing processes and raw material supply operations.
The signing ceremony was held at Merck Korea’s headquarters in Seoul, attended by Kim Young-im, head of Process Solutions at Merck Life Science Korea, and Shin Woong, head of operations at GC Biopharma.
According to the companies, the partnership will focus on strengthening cooperation related to raw material supply and manufacturing process operations required for biopharmaceutical production. The two sides also plan to establish a framework for process management and supply chain coordination.
GC Biopharma said the collaboration is expected to support production operations for key products including plasma-derived therapy “Alyglo” and Hunter syndrome treatment “Hunterase.”
Merck Life Science Korea will provide support related to raw material supply and production process technologies, the company said. The two companies also plan to hold regular technical meetings to share information on manufacturing processes and quality management.
GC Biopharma said the partnership is intended to support manufacturing operations and supply management for its biopharmaceutical portfolio.
Shin Woong, head of operations at GC Biopharma, said the company plans to expand cooperation in the production of major pharmaceutical products.
Kim Young-im, head of Process Solutions at Merck Life Science Korea, said the company will continue cooperation in manufacturing process operations and technical support.
